BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 30796033)

  • 1. Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors.
    Cooper JM; Patel AJ; Chen Z; Liao CP; Chen K; Mo J; Wang Y; Le LQ
    Clin Cancer Res; 2019 Jun; 25(11):3404-3416. PubMed ID: 30796033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.
    Patel AJ; Liao CP; Chen Z; Liu C; Wang Y; Le LQ
    Cell Rep; 2014 Jan; 6(1):81-92. PubMed ID: 24373973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor.
    Ikuta K; Ota T; Zhuo L; Urakawa H; Kozawa E; Hamada S; Kimata K; Ishiguro N; Nishida Y
    Int J Cancer; 2017 Jan; 140(2):469-479. PubMed ID: 27706810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
    Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
    Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
    Jin X; Yan Y; Wang D; Ding D; Ma T; Ye Z; Jimenez R; Wang L; Wu H; Huang H
    Mol Cell; 2018 Aug; 71(4):592-605.e4. PubMed ID: 30057199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Lopez G; Pollock RE
    Methods Mol Biol; 2017; 1510():365-374. PubMed ID: 27761835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
    Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
    Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
    Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.
    Peacock JD; Cherba D; Kampfschulte K; Smith MK; Monks NR; Webb CP; Steensma M
    J Transl Med; 2013 Sep; 11():213. PubMed ID: 24040940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
    Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
    Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase.
    Lee MJ; Tsai YJ; Lin MY; You HL; Kalyanam N; Ho CT; Pan MH
    Phytomedicine; 2019 Apr; 57():377-384. PubMed ID: 30831486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.